Revolution Medicines, Inc. G&A increased by 51.8% to $101.25M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 189.2%, from $35.01M to $101.25M. Over 4 years (FY 2021 to FY 2025), G&A shows an upward trend with a 59.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Rising G&A as a percentage of revenue may indicate organizational bloat, while stability suggests effective cost management.
Detailed definition
General and administrative expenses cover the overhead costs of running the business, including executive salaries, lega...
Peer comparison
Standard operating expense category; used to assess administrative leverage.
Metric ID:
general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.30M | $7.79M | $8.69M | $9.04M | $10.20M | $10.43M | $10.91M | $13.22M | $14.64M | $15.51M | $32.24M | $22.84M | $21.71M | $23.96M | $28.79M | $35.01M | $40.58M | $52.76M | $66.68M | $101.25M |
| QoQ Change | — | +6.8% | +11.6% | +4.0% | +12.9% | +2.3% | +4.6% | +21.2% | +10.7% | +6.0% | +107.9% | -29.2% | -4.9% | +10.4% | +20.2% | +21.6% | +15.9% | +30.0% | +26.4% | +51.8% |
| YoY Change | — | — | — | — | +39.8% | +33.9% | +25.5% | +46.3% | +43.5% | +48.7% | +195.5% | +72.7% | +48.3% | +54.5% | -10.7% | +53.3% | +86.9% | +120.2% | +131.6% | +189.2% |
Range$7.30M – $101.25M
CAGR+74.0%
Avg YoY Growth+73.7%
Median YoY Growth+51.0%
Current Streak7 quarters growth
G&A at Other Companies
Frequently Asked Questions
- What is Revolution Medicines, Inc.'s g&a?
- Revolution Medicines, Inc. (RVMD) reported g&a of $101.25M in Q1 2026.
- How has Revolution Medicines, Inc.'s g&a changed year-over-year?
- Revolution Medicines, Inc.'s g&a increased by 189.2% year-over-year, from $35.01M to $101.25M.
- What is the long-term trend for Revolution Medicines, Inc.'s g&a?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s g&a has grown at a 59.1% compound annual growth rate (CAGR), from $30.45M to $195.04M.
- What does g&a mean?
- The overhead costs required to manage and support the company's operations.